Graphic processing items (GPUs) and synthetic intelligence (AI) are among the many most searched phrases on-line today, making firms like NVIDIA NVDA the focus of buyers’ curiosity. Whereas NVIDIA’s inventory has surged 91.3% over the previous yr, rival chipmakers worldwide too are quickly increasing their presence, intensifying competitors within the international GPU area. With AI adoption accelerating throughout industries — from healthcare to finance — buyers are wanting to capitalize on something linked to this technological revolution.
Inside healthcare, particularly, over the previous couple of years, AI and GPUs have regularly revolutionized diagnostics, remedy and operational effectivity. NVIDIA not too long ago talked about its end-to-end BioNeMo platform, which is designed to speed up AI mannequin creation, customization and deployment for drug discovery and molecular design. The corporate famous that international pharmaceutical and TechBio business leaders, tutorial pioneers and AI researchers are adopting this open-source BioNeMo Framework to advance drug discovery and speed up molecule design. This isn’t all, in medical imaging and prognosis, the corporate’s Clara platform is gaining recognition for bettering the accuracy and pace of diagnosing circumstances reminiscent of most cancers, cardiovascular illnesses and neurological problems.
Contemplating this fast transformation, we focus on three healthcare shares with monumental progress prospects on this area of interest — Illumina ILMN, IQVIA IQV and Dexcom DXCM. These firms are leveraging AI developments to drive innovation in genomics, medical analysis and diabetes administration. With the growing adoption of AI-powered options, they’re well-positioned to capitalize on important funding alternatives within the close to future.
AI and Healthcare
Going by a Analysis and Markets report, globally, AI within the healthcare market is projected to succeed in $164.16 billion by 2030 from $14.92 billion in 2024, at a CAGR of 49.1% throughout the forecast interval.
Picture Supply: Analysis and Markets
As per the report, the cloud-based phase is anticipated to witness the best progress resulting from its benefits, together with seamless knowledge integration, distant accessibility, value effectivity, safety and scalability. The growing demand for distant healthcare companies and telemedicine additional accelerates adoption. Additional, AI functions like predictive analytics, medical resolution help, and medical imaging integration are going to reinforce operational effectivity.
General, AI-powered imaging, fueled by high-performance GPUs, permits sooner and extra correct illness detection in radiology and pathology. In drug discovery, AI accelerates molecular simulations, lowering improvement timelines. Personalised medication is advancing as AI analyzes huge datasets to tailor therapies. Robotics-assisted surgical procedures have gotten extra exact, bettering affected person outcomes. Moreover, AI-driven administrative instruments optimize hospital workflows and scale back prices. As AI and GPUs proceed to evolve, the healthcare sector stands to realize from unprecedented enhancements in affected person care and effectivity.
3 Excessive-Development Healthcare Shares
Illumina: In 2025, this famend life sciences firm introduced a collaboration with NVIDIA to advance expertise platforms for analyzing and decoding multiomic knowledge. By combining developments in AI with multiomic knowledge at scale, the partnership seeks to optimize the evaluation of huge quantities of knowledge concerned in multiomic analysis.
Moreover, Illumina plans to include fashions developed by the NVIDIA Biology Basis Mannequin Analysis Crew into its choices. This integration will permit prospects to leverage these fashions alongside their proprietary datasets, bettering efficiency in duties reminiscent of cell state prediction and gene transcription evaluation.
The inventory has a Zacks Rank #3 (Maintain) and a long-term anticipated earnings progress charge of 13.4%. In 2025, Illumina is anticipated to file earnings progress of 83.3%.
Illumina, Inc. Value
Illumina, Inc. price | Illumina, Inc. Quote
IQVIA: The corporate is actively advancing the mixing of AI in healthcare, specializing in enhancing affected person outcomes and streamlining life sciences operations. Its strategy, termed healthcare-grade AI, emphasizes knowledge privateness, regulatory compliance and affected person security. IQV, too, partnered with NVIDIA earlier in 2025 to make the most of the NVIDIA AI Foundry. This collaboration permits IQVIA to create customized basis fashions based mostly on its huge knowledge and experience, growing agentic AI options to advance functions in healthcare and life sciences.
This Zacks Rank #3 firm has a long-term historic earnings progress of 12.4%. In 2025 and 2026, IQVIA is anticipated to report earnings progress of 6.5% and 11.7%, respectively.
IQVIA Holdings Inc. Value
IQVIA Holdings Inc. price | IQVIA Holdings Inc. Quote
Dexcom: This steady glucose monitoring programs (CGM) developer launched a proprietary GenAI platform, changing into the primary CGM producer to combine GenAI into glucose biosensing expertise. The preliminary software of this expertise is present in Dexcom’s over-the-counter glucose biosensor, Stelo. Dexcom developed this GenAI platform in collaboration with Google Cloud, using the Vertex AI platform and Gemini fashions.
This Zacks Rank #3 firm has a long-term historic earnings progress charge of 29.7%. In 2025 and 2026, DXCM is anticipated to report earnings progress of 20.7% and 21.6%, respectively.
You possibly can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DexCom, Inc. Value
DexCom, Inc. price | DexCom, Inc. Quote
Solely $1 to See All Zacks’ Buys and Sells
We’re not kidding.
A number of years in the past, we shocked our members by providing them 30-day entry to all our picks for the overall sum of solely $1. No obligation to spend one other cent.
1000’s have taken benefit of this chance. 1000’s didn’t – they thought there should be a catch. Sure, we do have a purpose. We wish you to get acquainted with our portfolio companies like Shock Dealer, Shares Below $10, Know-how Innovators,and extra, that closed 256 positions with double- and triple-digit positive factors in 2024 alone.
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
